Management of Anemia among Chronic Hemodialysis Patients: Monocentric Study of MoroccoJournal: International Journal of Science and Research (IJSR) (Vol.7, No. 7)
Publication Date: 2018-07-05
Authors : Wafaa Arache; Driss El Kabbaj;
Page : 514-516
Keywords : anemia; chronic kidney disease; hemodialysis; erythropoiesis stimulating agents;
One of the most common complications associated with chronic renal failure is anemia, which can lead to clinical disturbances and may also potentiate other underlying cardiac complications, such as left ventricular hypertrophy. and arrhythmia. The purpose of this work is to report the means of anemia management for chronic hemodialysis patients in the Nephrology and Dialysis department of the Rabat Military Hospital of Morocco. Methods This was a single-center retrospective study conducted in the Department of Renal Dialysis and Renal Transplantation at the Mohammed V Military Training Hospital in Rabat from March 1, 2017 to March 1, 2018 for all our chronic hemodialysis patients. Results During the study period, records of 40 chronic hemodialysis patients were analyzed. The mean age of the patients was 50 years 16.55 years with extremes ranging from 20 to 85 years, sex ratio (m / f) was 1.1. Average seniority in hemodialysis was 60 months.89 % of the included patients received treatment with subcutaneous erythropoiesis stimulating agents. Correction of iron deficiency was performed in 42 % of patients with injectable iron. Conclusion The management of anemia is based essentially on the prescription of stimulating agents erythropoiesis thus avoiding transfusions and overloads martial.
Other Latest Articles
Last modified: 2021-06-28 19:21:40